ArticleScience (New York, N.Y.)2020
Remembering seasonal coronaviruses.
Article in Science (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Article
- Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody Responses.Research square · 2025Article
- Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2.The Journal of experimental medicine · 2025Article
- Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody Responses.bioRxiv : the preprint server for biology · 2025Article
- The Effect of Preexisting Coronavirus Antibodies on Severe Acute Respiratory Syndrome Coronavirus 2 Infection Outcomes in Exposed Household Members.The Journal of infectious diseases · 2025Article
- Minimal Impact of Prior Common Cold Coronavirus Exposure on Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination or Infection Risk in Older Adults in Congregate Care.Open forum infectious diseases · 2025Article
- The Influence of Cross-Reactive T Cells in COVID-19.Biomedicines · 2024Review
- SARS-CoV-2 spike S2-specific neutralizing antibodies.Emerging microbes & infections · 2023Review
- Article
- Article
- Counterfactuals of effects of vaccination and public health measures on COVID-19 cases in Canada: what could have happened?Frontiers in public health · 2023Article
- Immune recall improves antibody durability and breadth to SARS-CoV-2 variants.Science immunology · 2022Article
- A common allele of HLA mediates asymptomatic SARS-CoV-2 infection.medRxiv : the preprint server for health sciences · 2022Article
- Application of animal models to compare and contrast the virulence of current and future potential SARS-CoV-2 variants.Biosafety and health · 2022Review
- Memory B cell diversity: insights for optimized vaccine design.Trends in immunology · 2022Review
- The immunology and immunopathology of COVID-19.Science (New York, N.Y.) · 2022Review
- Cross-reactive antibodies against human coronaviruses and the animal coronavirome suggest diagnostics for future zoonotic spillovers.Science immunology · 2021Article
- The link between microglia and the severity of COVID-19: The "two-hit" hypothesis.Journal of medical virology · 2021Article
- Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2021Article
- Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.Annals of neurology · 2021Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33303605What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.